Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCL21 (chemokine [C-C motif] ligand 21) is a small cytokine belonging to the CC chemokine family. It is also known as 6Ckine due to its six conserved cysteine residues, exodus-2, and secondary lymphoid-tissue chemokine (SLC). CCL21 primarily functions by binding to the cell surface receptor CCR7. Its main biological role is guiding CCR7-expressing leukocytes—such as T cells and dendritic cells—to secondary lymphoid organs like lymph nodes and Peyer’s patches[5]. CCL21 has an extended C-terminal region that allows it to interact with extracellular matrix components; cleavage of this tail produces a soluble form with distinct functional properties[5]. Mechanistically, CCL21 induces chemotaxis of immune cells via activation of CCR7 and downstream signaling pathways such as MEK-ERK[3][6]. In cancer immunotherapy research, recombinant or gene-modified forms of CCL21 are being explored for their ability to attract antigen-presenting cells and cytotoxic effectors into tumors to enhance anti-tumor immunity[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ccl21.